Get started
Moderna, Inc.Moderna, Inc.Moderna, Inc.

Moderna, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Moderna, Inc.



Key facts today


Moderna (MRNA) jumped 14% to a 52-week high after Phase 3 INTerpath-001 with Intismeran plus KEYTRUDA met primary RFS and key DMFS endpoints; nine more Phase 2/3 INTerpath trials planned. 1
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪89.83 B‬ USDLarge cap
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−7.98 USD
Net income (FY)
‪−2.82 B‬ USD
Revenue (FY)
‪1.94 B‬ USD
Shares float
‪365.28 M‬
Beta (1Y)
0.23

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪4.7 K‬
Change (1Y)
‪−1.1 K‬−18.97%
Revenue / Employee (1Y)
‪413.62 K‬ USD
Net income / Employee (1Y)
‪−600.43 K‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Stéphane Bancel
Website
modernatx.com
Headquarters
Cambridge
Founded
2010
IPO date
Dec 7, 2018
ISIN
US60770K1079
CUSIP
60770K107
FIGI
BBG003PHHZT1
Identifiers
ISIN US60770K1079
CFI code
ESVUFR
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral

Analyst rating


An aggregate view of professional's ratings.
Neutral
Neutral
Neutral

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


— YTM
Maturity dateMar 1, 2032
Coupon0% (Zero)

See all MRNA bonds 

ETFs holding the stock


QQQ
Invesco QQQ Trust, Series 1
Weight0.37%
Market value‪1.87 B‬
VTI
Vanguard Morningstar Total Stock Market ETF
Weight0.07%
Market value‪1.59 B‬
VOO
Vanguard S&P 500 ETF
Weight0.07%
Market value‪1.32 B‬
VB
Vanguard Morningstar Small-Cap ETF
Weight0.62%
Market value‪1.15 B‬
IVV
iShares Core S&P 500 ETF
Weight0.12%
Market value‪1.06 B‬
SPY
SPDR S&P 500 ETF TRUST
Weight0.12%
Market value‪1.02 B‬
VBR
Vanguard Morningstar Small-Cap Value ETF
Weight1.07%
Market value‪732.31 M‬
IBB
iShares Biotechnology ETF
Weight5.65%
Market value‪606.28 M‬
XLV
State Street Health Care Select Sector SPDR ETF
Weight1.35%
Market value‪596.09 M‬
CGGR
Capital Group Growth ETF
Weight1.99%
Market value‪530.58 M‬
QQQM
Invesco NASDAQ 100 ETF
Weight0.37%
Market value‪416.70 M‬

Explore more ETFs 

Frequently asked questions


The current price of MRNA is 213.74 USD — it has decreased by −0.98% in the past 24 hours. Watch Moderna, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moderna, Inc. stocks are traded under the ticker MRNA.
MRNA stock has risen by 16.39% compared to the previous week, the month change is a 61.55% rise, over the last year Moderna, Inc. has showed a 669.40% increase.
We've gathered analysts' opinions on Moderna, Inc. future price: according to them, MRNA price has a max estimate of 200.00 USD and a min estimate of 40.00 USD. Watch MRNA chart and read a more detailed Moderna, Inc. stock forecast: see what analysts think of Moderna, Inc. and suggest that you do with its stocks.
MRNA reached its all-time high on Aug 10, 2021 with the price of 497.49 USD, and its all-time low was 11.54 USD and was reached on Aug 7, 2019. View more price dynamics on MRNA chart.
See other stocks reaching their highest and lowest prices.
MRNA stock is 7.85% volatile and has beta coefficient of 0.23. Track Moderna, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moderna, Inc. there?
Today Moderna, Inc. has the market capitalization of ‪89.83 B‬, it has decreased by −2.65% over the last week.
Yes, you can track Moderna, Inc. financials in yearly and quarterly reports right on TradingView.
Moderna, Inc. is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
MRNA earnings for the last quarter are −1.97 USD per share, whereas the estimation was −2.03 USD resulting in a 3.06% surprise. The estimated earnings for the next quarter are −1.10 USD per share. See more details about Moderna, Inc. earnings.
Moderna, Inc. revenue for the last quarter amounts to ‪145.00 M‬ USD, despite the estimated figure of ‪102.93 M‬ USD. In the next quarter, revenue is expected to reach ‪892.40 M‬ USD.
MRNA net income for the last quarter is ‪−782.00 M‬ USD, while the quarter before that showed ‪−1.34 B‬ USD of net income which accounts for 0.00% change. Track more Moderna, Inc. financial stats to get the full picture.
No, MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 13, 2026, the company has ‪4.7 K‬ employees. See our rating of the largest employees — is Moderna, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Moderna, Inc. EBITDA is ‪−3.08 B‬ USD, and current EBITDA margin is −147.07%. See more stats in Moderna, Inc. financial statements.
Like other stocks, MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moderna, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moderna, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moderna, Inc. stock shows the strong buy signal. See more of Moderna, Inc. technicals for a more comprehensive analysis.